文献速递骨软组织肉瘤与黑色素瘤

CMB305联合阿替利珠单抗对比阿替利珠单抗单药治疗表达NY-ESO-1的软组织肉瘤的II期随机研究

Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
PubMed 文献 · J Clin Oncol · 2021-07-14

这项开放标签随机II期试验纳入89例局部晚期、复发或转移性滑膜肉瘤或黏液样脂肪肉瘤患者,随机接受CMB305联合阿替利珠单抗或阿替利珠单抗单药治疗。联合组与对照组中位PFS分别为2.6个月和1.6个月(HR 0.9,95%CI 0.6-1.3),两组中位OS均为18个月;联合组治疗诱导的NY-ESO-1特异性T细胞和抗体应答率显著更高。

要点

  • 联合组与对照组中位PFS分别为2.6个月和1.6个月(HR 0.9,95%CI 0.6-1.3)。
  • 两组中位OS均为18个月,联合治疗未显著改善PFS或OS。
  • 联合组NY-ESO-1特异性T细胞和抗体应答率显著更高。

核心结论

  • CMB305联合阿替利珠单抗对比阿替利珠单抗单药未显著增加PFS或OS。
  • 部分患者出现抗NY-ESO-1免疫应答,且影像学上似乎优于无应答者。

研究设计与样本

  • 开放标签随机II期试验,纳入89例局部晚期、复发或转移性滑膜肉瘤或黏液样脂肪肉瘤(任何级别)患者。
  • 患者随机接受CMB305联合阿替利珠单抗(实验组)或阿替利珠单抗单药(对照组),主要终点为PFS和OS,采用Kaplan-Meier法分析。

主要发现

  • 联合组与对照组中位PFS分别为2.6个月和1.6个月(HR 0.9,95%CI 0.6-1.3)。
  • 两组中位OS均为18个月。
  • 联合组治疗诱导的NY-ESO-1特异性T细胞应答率显著更高(P = .01),NY-ESO-1特异性抗体应答率也显著更高(P < .0001)。
  • 事后分析中,出现抗NY-ESO-1 T细胞免疫应答的患者OS更长(36个月;HR 0.3;P = .02)。

关键数值与推荐

  • 55.1%的患者既往接受过≥2线化疗。
  • 联合组与对照组中位PFS分别为2.6个月和1.6个月(HR 0.9,95%CI 0.6-1.3)。
  • 两组中位OS均为18个月。
  • 联合组NY-ESO-1特异性T细胞应答率更高(P = .01),抗体应答率更高(P < .0001)。
  • 事后分析中出现抗NY-ESO-1 T细胞免疫应答者OS为36个月(HR 0.3;P = .02)。

临床怎么用

  • CMB305联合阿替利珠单抗未显著改善滑膜肉瘤或黏液样脂肪肉瘤患者的PFS或OS。
  • 治疗诱导的NY-ESO-1免疫应答与更好的OS相关,但需进一步验证。
  • 联合治疗的安全性及免疫应答需在临床中评估。

局限性

  • 事后分析中免疫应答与OS的关联需前瞻性研究验证。
  • 样本量较小(89例),可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CMB305 is a heterologous prime-boost vaccination regimen created to prime NY-ESO-1-specific CD8 T-cell populations and then activate the immune response with a potent TLR-4 agonist. This open-label randomized phase II trial was designed to investigate the efficacy and safety of adding the CMB305 regimen to atezolizumab (anti-programmed death ligand-1 therapy) in comparison with atezolizumab alone in patients with synovial sarcoma or myxoid liposarcoma. PATIENTS AND METHODS: Patients with locally advanced, relapsed, or metastatic synovial sarcoma or myxoid liposarcoma (any grade) were randomly assigned to receive CMB305 with atezolizumab (experimental arm) or atezolizumab alone (control arm). The primary end points were progression-free survival (PFS) and overall survival (OS) analyzed using the Kaplan-Meier method. Safety and immune responses were assessed. RESULTS: A total of 89 patients were enrolled; 55.1% had received ≥ 2 prior lines of chemotherapy. Median PFS was 2.6 months and 1.6 months in the combination and control arms, respectively (hazard ratio, 0.9; 95% CI, 0.6 to 1.3). Median OS was 18 months in both treatment arms. Patients treated with combination therapy had a significantly higher rate of treatment-induced NY-ESO-1-specific T cells (P = .01) and NY-ESO-1-specific antibody responses (P < .0001). In a post hoc analysis of all dosed patients, OS was longer (36 months) in the subset who developed anti-NY-ESO-1 T-cell immune response (hazard ratio, 0.3; P = .02). CONCLUSION: Although the combination of CMB305 and atezolizumab did not result in significant increases in PFS or OS compared with atezolizumab alone, some patients demonstrated evidence of an anti-NY-ESO-1 immune response and appeared to fare better by imaging than those without such an immune response. Combining prime-boost vaccines such as CMB305 with anti-programmed death ligand-1 therapies merits further evaluation in other clinical contexts.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chawla SP, Van Tine BA, Pollack SM, et al. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. J Clin Oncol. 2021. PMID: 34260265. doi:10.1200/JCO.20.03452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。